Phase IV Study of Concomitant Administration of the sIPV and HepA

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

August 15, 2026

Study Completion Date

December 15, 2027

Conditions
PolioHepatitis A
Interventions
BIOLOGICAL

sIPV (booster dose at 18 months of age)

Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose at 18 months of age for the booster one

BIOLOGICAL

HepA-L

Freeze-dried/lyophilized live-attenuated hepatitis A virus vaccine, 1.0mL for each dose at 18 months of age

BIOLOGICAL

HepA-I

Inactivated hepatitis A virus vaccine, 0.5mL for each dose, two doses at 18 and 24 months of age, respectively

Trial Locations (3)

Unknown

Jiu Longpo District Center for Disease Control and Disease, Chongqing

Wanzhou District Center for DIsease Control and Prevention, Chongqing

Jiangjin District Center for Disease Control and Prevention, Chongqing

All Listed Sponsors
lead

Institute of Medical Biology, Chinese Academy of Medical Sciences

OTHER

NCT06460545 - Phase IV Study of Concomitant Administration of the sIPV and HepA | Biotech Hunter | Biotech Hunter